Abiopharma

🔍 Locoh-Donou Francois (Director)

Company: F5, INC. (FFIV)

Report Date: 2026-05-05

Detailed Transactions and Holdings:

• Sold 40 shares of Common Stock at $331.05 per share (Direct)
  Date: 2026-05-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 150,732.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 200 shares of Common Stock at $332.522 per share (Direct)
  Date: 2026-05-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 150,532.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 80 shares of Common Stock at $335.275 per share (Direct)
  Date: 2026-05-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 150,452.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 1,332 shares of Common Stock at $336.9244 per share (Direct)
  Date: 2026-05-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 149,120.00 | transaction_form_type: 4 | Footnotes: F4
• Sold 1,268 shares of Common Stock at $337.7807 per share (Direct)
  Date: 2026-05-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 147,852.00 | transaction_form_type: 4 | Footnotes: F5
• Sold 480 shares of Common Stock at $338.6025 per share (Direct)
  Date: 2026-05-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 147,372.00 | transaction_form_type: 4 | Footnotes: F6
• Sold 383 shares of Common Stock at $339.8752 per share (Direct)
  Date: 2026-05-05 | Code: S | equity_swap_involved: 0 | shares_owned_after: 146,989.00 | transaction_form_type: 4 | Footnotes: F7
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-05-05 | Code: H | nature_of_ownership: By Family Trust | shares_owned_after: 42,000.00 | Footnotes: F8

Footnotes:

• F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan dated 12/03/2025.
• F2: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $332.05 to $332.98. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
• F3: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $334.99 to $335.56. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
• F4: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $336.35 to $337.34. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
• F5: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $337.35 to $338.24. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
• F6: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $338.38 to $339.04. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
• F7: The price in Column 4 is a weighted average sale price. The prices actually received ranged from $339.51 to $340.27. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
• F8: These shares are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the trust.